Last reviewed · How we verify
Nab-paclitaxel Combined With Bevacizumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Nab-paclitaxel Combined With Bevacizumab (Nab-paclitaxel Combined With Bevacizumab) — Peking University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nab-paclitaxel Combined With Bevacizumab TARGET | Nab-paclitaxel Combined With Bevacizumab | Peking University | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nab-paclitaxel Combined With Bevacizumab CI watch — RSS
- Nab-paclitaxel Combined With Bevacizumab CI watch — Atom
- Nab-paclitaxel Combined With Bevacizumab CI watch — JSON
- Nab-paclitaxel Combined With Bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). Nab-paclitaxel Combined With Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/nab-paclitaxel-combined-with-bevacizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab